Shell Asset Management Co. held its position in shares of Insys Therapeutics, Inc. (NASDAQ:INSY) during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 34,223 shares of the specialty pharmaceutical company’s stock at the end of the second quarter. Shell Asset Management Co.’s holdings in Insys Therapeutics were worth $433,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of INSY. Eqis Capital Management Inc. boosted its position in shares of Insys Therapeutics by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 66,121 shares of the specialty pharmaceutical company’s stock valued at $836,000 after buying an additional 404 shares in the last quarter. American International Group Inc. boosted its position in shares of Insys Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock valued at $152,000 after buying an additional 953 shares in the last quarter. Credit Suisse AG boosted its position in shares of Insys Therapeutics by 8.2% in the first quarter. Credit Suisse AG now owns 31,003 shares of the specialty pharmaceutical company’s stock valued at $326,000 after buying an additional 2,362 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Insys Therapeutics by 5.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 79,468 shares of the specialty pharmaceutical company’s stock valued at $836,000 after buying an additional 4,275 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Insys Therapeutics by 30.3% in the first quarter. Wells Fargo & Company MN now owns 27,541 shares of the specialty pharmaceutical company’s stock valued at $289,000 after buying an additional 6,407 shares in the last quarter. Institutional investors and hedge funds own 27.85% of the company’s stock.

Shares of Insys Therapeutics, Inc. (INSY) opened at 9.27 on Wednesday. Insys Therapeutics, Inc. has a 52-week low of $8.70 and a 52-week high of $18.42. The stock’s market cap is $673.89 million. The stock’s 50 day moving average is $11.62 and its 200 day moving average is $11.43.

Insys Therapeutics (NASDAQ:INSY) last released its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.12. The business had revenue of $42.60 million for the quarter, compared to analyst estimates of $36.90 million. Insys Therapeutics had a negative net margin of 9.63% and a negative return on equity of 3.02%. The company’s quarterly revenue was down 38.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.13 earnings per share. On average, equities analysts expect that Insys Therapeutics, Inc. will post ($0.29) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/16/shell-asset-management-co-holds-stake-in-insys-therapeutics-inc-insy.html.

Several brokerages have recently weighed in on INSY. Royal Bank Of Canada set a $16.00 target price on Insys Therapeutics and gave the stock a “buy” rating in a report on Saturday, June 3rd. BidaskClub upgraded Insys Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, July 8th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Insys Therapeutics in a report on Tuesday, July 4th. Piper Jaffray Companies set a $10.00 target price on Insys Therapeutics and gave the stock a “hold” rating in a report on Wednesday, July 26th. Finally, Zacks Investment Research cut Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $13.25.

In other Insys Therapeutics news, Director Rohit Vishnoi purchased 4,000 shares of the stock in a transaction dated Thursday, June 1st. The shares were acquired at an average cost of $14.14 per share, for a total transaction of $56,560.00. Following the completion of the transaction, the director now directly owns 4,000 shares of the company’s stock, valued at $56,560. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director Steven J. Meyer purchased 8,000 shares of the stock in a transaction dated Thursday, May 18th. The stock was acquired at an average price of $12.21 per share, for a total transaction of $97,680.00. Following the completion of the transaction, the director now directly owns 52,083 shares of the company’s stock, valued at $635,933.43. The disclosure for this purchase can be found here. Insiders bought 40,400 shares of company stock worth $419,515 over the last quarter. Company insiders own 67.90% of the company’s stock.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Want to see what other hedge funds are holding INSY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insys Therapeutics, Inc. (NASDAQ:INSY).

Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Stock Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related stocks with our FREE daily email newsletter.